Search Results 101-110 of 16974 for Antagonist

1. Trial To Evaluate Anticoagulation Therapy In Hemodialysis Patients With Atrial Fibrillation - Mayo Clinic

   Need for aspirin at a dose > 81 mg a day or need for P2Y12 antagonist therapy (for example clopidogrel, prasugrel, or ticagrelor); Life expectancy < 3 months ...

2. Outcomes of Percutaneous Revascularization for Management of Surgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease: A Prospective Registry - Mayo Clinic

   Established iodine allergy that cannot be managed medically, allergy to everolimus, or absolute contraindication to aspirin, P2Y12 antagonist therapy with ...

3. Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) - Mayo Clinic

   ... antagonists unless medication is held for five half-lives prior to study; laboratory evidence of significant anemia, as defined by a hemoglobin level 1 gm/dL ...

4. Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction - Mayo Clinic

   ... antagonists;; No change in dosage of ACE, ARBs, beta-blockers, CCBs or aldosterone antagonists of more than 100%. Elevated NT-proBNP (>300 pg/ml) or BNP ...

5. A Study To Examine The Long-Term Safety, Tolerability And Effectiveness Of APL-130277 For The Acute Treatment Of "OFF" Episodes In Patients With Parkinson's Disease - Mayo Clinic

   ... antagonists (excluding quetiapine and clozapine) or dopamine depleting agents; Drug or alcohol dependency in the past 12 months; History of malignant melanoma ...

6. Functioning gonadotroph macroadenoma causing ovarian hyperstimulation: A case from the endocrine teaching clinics

   While dopamine agonists and somatostatin analogues have decreased ovarian volumes and gonadotropin secretion in a limited number of cases, Gn-RH antagonists ...

7. Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia - Mayo Clinic

   ... antagonist, or pancreatic enzymes are not eligible; intermittent usage of antacids or H2 antagonists are allowed. Patients who have a systemic infection ...

8. Study of Sparsentan in Patients with Primary Focal Segmental Glomerulosclerosis - Mayo Clinic

   The patient has a history of serious side effect or allergic response to any angiotensin II antagonist or endothelin receptor antagonist, including ...

9. Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

   ... antagonist or a stable dose of corticosteroid from a prior chemotherapy regimen must discontinue the agent for at least 4 weeks prior to enrollment.

10. Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer - Mayo Clinic

    antagonists and antacids are allowed - Patients who cannot discontinue drugs that are strong inhibitors of CYP3A4 or CYP1A2 - Patients who cannot ...